The most valuable data in healthcare is often the data you can't get. For a patient with a prosthetic limb or a diabetic foot ulcer, the critical metrics of fit, pressure, and gait happen out of the clinic, over weeks and months of daily use. Capturing that data requires sensors that are not just accurate, but soft, stretchable, and durable enough to live inside the product itself. Sendance, a 2021 spinout from Johannes Kepler University Linz, is betting that its patented conformable sensor grids and cloud platform are the missing layer to turn passive medical and sports devices into regulated data services.
A Wedge in Soft Materials
Sendance's core proposition is a B2B platform, not a consumer gadget. The company provides manufacturers of orthopedic braces, prosthetic sockets, smart insoles, and sports wearables with two integrated components: the 'sendance-grid' and the 'sendance-cloud' [Perplexity Sonar Pro Brief]. The grid is a thin, permeable sensor array that can be embedded into textiles, foam, or 3D-printed plastics. It is designed to stretch, conform to complex surfaces, and withstand the high pressures of daily use [OTWorld, 2026]. The cloud platform handles the data pipeline, from visualization to secure storage compliant with regulations like GDPR [OTWorld, 2026].
The wedge is time-to-market. For a device manufacturer, developing a reliable, medically-graded sensor system from scratch is a multi-year R&D project. Sendance claims its 'Smart Product-as-a-Service' offering can accelerate that process by a factor of six [Advantage Austria]. The company works with customers to iteratively develop prototypes until reaching product maturity, with automated production ready for launch [Medizintechnik-Cluster]. The goal is to let an orthotics company focus on its core biomechanical expertise while Sendance handles the sensorization and data infrastructure.
The Academic Spinout Engine
The company's technical credibility is rooted in its origin. Sendance was founded as a spin-off from the LIT Soft Materials Lab at JKU Linz, and the founding team carries deep expertise in soft materials and stretchable electronics [Tech2b]. This academic heritage is a double-edged sword: it provides a formidable technical moat but also frames the commercial challenge of transitioning from lab prototypes to scaled, reliable manufacturing.
The leadership team reflects this blend of deep tech and commercial pragmatism.
| Role | Name | Note |
|---|---|---|
| Co-founder & CEO | Robert Koeppe | Leads business strategy and external partnerships [Spotify, 2026]. |
| Co-founder | Daniela Wirthl | Materials science expert from the JKU lab; featured in industry podcasts [Interview der Woche Podcast, 2026]. |
| Co-founder & CTO | Yana Vereshchaga | Leads technical development and product architecture [LinkedIn, 2026]. |
| Co-founder & CFO | Thomas Stockinger | Manages finance, operations, and grants [Prospeo]. |
The company has also added Tim Juergens to its advisory board, suggesting a move to bolster its commercial and strategic guidance [LinkedIn, 2026].
Funding and the Path to Scale
Financing for a hardware-and-software deep-tech play is complex. Sendance's funding history shows a mix of venture capital, state aid, and EU grants, which is a common pattern for European deep-tech startups tackling regulated markets.
| Metric | Value |
|---|---|
| Pre-seed (Feb 2023) | 355.7 k USD |
| State Aid FFG (2024-2026) | 247 k EUR |
| Total Disclosed Capital | 2600 k EUR |
According to Dealroom, the company has raised a total of €2.6 million to date [Dealroom.co, 2026]. This includes a $355,729 pre-seed round in early 2023 [Crunchbase, Feb 2023] and a subsequent seed round led by Garage Angels in July 2023 [Trending Topics, July 2023]. A significant portion of its capital, €246,980, comes from a state aid grant through the Austrian Research Promotion Agency (FFG) for the 2024-2026 period [Northdata, 2024]. This grant funding is non-dilutive and often tied to specific R&D milestones, reducing near-term burn rate but adding reporting overhead.
The Realistic Competitive Set
For a procurement officer at a mid-sized orthotics manufacturer evaluating Sendance, the competitive landscape isn't crowded with direct clones. The realistic alternatives tend to fall into distinct buckets.
- In-house development. The default option for large medtech players with ample budgets and engineering teams. The trade-off is time, cost, and distraction from core product roadmaps.
- Specialized sensor startups. Companies like ReTiSense, which is named as a competitor in Sendance's structured data, likely offer point solutions for specific sensing modalities. Sendance's differentiation is its focus on conformable, textile-integrated grids and its bundled cloud data platform as a service.
- Generic IoT platforms. Major cloud providers offer robust data pipelines, but they lack the domain-specific sensor hardware, the understanding of regulated health data, and the pre-integrated solution for medical device manufacturers.
Sendance's ideal customer profile is a product manager or R&D lead at a manufacturer of assistive devices, orthopedic products, or high-end sports equipment. This is a buyer who is feeling pressure to add digital and data-driven features to their physical products, who understands the long certification cycles in medical tech, and who lacks the in-house expertise to build a reliable sensing system from the substrate up. They are not buying a sensor; they are buying a de-risked path to a 'smart' product line with a recurring service revenue stream.
Where the Wheels Could Come Off
The bet is compelling, but the risks are inherent in the model. Hardware scaling is notoriously difficult, and yield rates for soft, stretchable electronics can make or destroy margins. The sales cycle in medical devices is long, often stretching 18-24 months from first contact to a paid pilot, which tests a startup's capital endurance. Furthermore, while the €91 billion market for assistive devices and connected health wearables is frequently cited [F6S], it is a broad category. Sendance's success depends on capturing specific, high-value niches within it, such as prosthetic liners or diabetic wound monitoring, where continuous pressure data is clinically actionable.
The company's answer to these risks appears to be its phased, partnership-heavy approach. By engaging in iterative prototype development with customers and leveraging non-dilutive grant funding, it can extend its runway and de-risk the technical integration before committing to full-scale production. The next twelve months will be critical for transitioning from successful prototypes to announced commercial deployments with named device manufacturers. Landing a flagship partnership with a recognized brand in orthotics or sports medicine would be the strongest possible signal that the platform works not just in the lab, but in the field.
Sources
- [Interview der Woche Podcast, 2026] Daniela Wirthl feature | https://www.podcast.de/podcast/3293608/interview-der-woche
- [LinkedIn, 2026] Yana Vereshchaga role as CTO | https://at.linkedin.com/company/sendance-gmbh
- [LinkedIn, 2026] Tim Juergens advisory board appointment | https://at.linkedin.com/company/sendance-gmbh
- [Crunchbase, Feb 2023] Pre-seed round details | https://www.crunchbase.com/funding_round/sendance-pre-seed--4a85f185